Drug Safety Research Unit and pharmacoepidemiology Saad ShakirLynda Wilton Editorial 23 December 2012 Pages: 1 - 2
Counting the costs of specialisation and of revalidation Robert N. Smith Editorial 23 December 2012 Pages: 2 - 4
Defining the spectrum of appropriate prescribing: implications for effective medicines management Martin FrischerH. HeatlieD. Millson Original Article 23 December 2012 Pages: 17 - 21
Good Clinical Practice and study monitoring: results of an Italian survey of the clinical monitor Francesco De TomasiC. Zanna Original Article 23 December 2012 Pages: 23 - 25
Collaborative networks with private doctors to conduct joint clinical studies in Leipzig/Germany Hans-Detlev StahlF. Emmrich Original Article 23 December 2012 Pages: 27 - 28
The development of quality assurance within the Medicines Control Agency David B. Jefferys Original Article 23 December 2012 Pages: 29 - 32
Pharmaceutical medicine and academic clinical pharmacology: a convergent pathway? Colin T. Dollery Point of View 23 December 2012 Pages: 33 - 36
Should serious adverse events requiring expedited regulatory reporting be unblinded? John E. GaitD. Goldsmith Point of View 23 December 2012 Pages: 37 - 39
Higher medical training in pharmaceutical medicine: Delphi exercise on drug safety surveillance and statistics and data management advanced modules H. F. BoardmanD. S. MillsonM. J. Phelan Education 23 December 2012 Pages: 47 - 51
The Adrian Salter Lecture Donna Ellender Society of Pharmaceutical Medicine 23 December 2012 Pages: 57 - 58
First Report of the Ethics Sub-Group Frank WellsMartin W. LunnonPharmacogenetics Working Party Society of Pharmaceutical Medicine 23 December 2012 Pages: 58 - 58
